/Investor DB

Lilly Asia Ventures — 2019 Investments

2 investments dated 2019 · listed companies and verified rows first · show all

Passage Biopassagebio.comin𝕏NASDAQ: PASGFeb 2019

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in

BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFrazier Life SciencesAccess BiotechnologyFrazier Healthcare PartnersNew Leaf Venture PartnersOrbiMedSphera Funds Management+2 more

Insilico Medicineinsilico.comin𝕏Sep 2019✓ verified

Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.

AI & Machine LearningBiotechDigital HealthHealthtechHong Kong, US

Aleksandrs Zavoronkovs(Executive Officer, Director)Alex Zavoronkov(Director)Alex Zhavoronkov(Founder)inAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in

BoardNisa Leung(Director)in

PartnerHongbo Lu· solo GP

Co-investorsOrbiMedQiming Venture PartnersWarburg PincusBaidu VenturesEight Roads VenturesLake Bleu Capital+16 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.